Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic with at least 3.8 million deaths to date. For that reason, finding an efficient vaccine for this virus quickly became a global priority. The majority of vaccines now marketed are based on the SARS-CoV-2 spike protein that has been described as the keystone for optimal immunization. In order to monitor SARS-CoV-2 spike-specific humoral responses generated by immunization or infection, we have developed a robust and reproducible enzyme-linked immunosorbent assay (ELISA) protocol. This protocol describes a method for quantitative detection of IgG antibodies against the SARS-CoV-2 spike protein using antigen-coated microtiter plates. Results showed that antibodies could be quantified between the range of 1.953 ng/mL to 500 ng/mL with limited inter- and intra-assay variability.
Highlights
2 (SARS-CoV-2), has triggered a worldwide pandemic with over 176 million confirmed cases globally and more than 3.8 million deaths as of June 2021 [1]. In response to this major public health crisis, global efforts have been dedicated to developing different SARSCoV-2 vaccines using a variety of technologies [2,3,4,5,6] and the SARS-CoV-2 spike protein
The SARS-CoV-2 spike protein has often been described as the keystone for obtaining an optimal and efficient immunization by eliciting neutralizing antibodies and targeting the structural domains of the S protein: S1 RBD, S1 N-terminal domain, or the S2 region [7,8]
We have developed a robust and reproducible enzyme-linked immunosorbent assay (ELISA) protocol
Summary
In order to monitor SARS-CoV-2 spike-specific humoral responses generated by immunization or infection, we have developed a robust and reproducible enzyme-linked immunosorbent assay (ELISA) protocol. This protocol describes a method for quantitative detection of IgG antibodies against the SARS-CoV-2 spike protein using antigen-coated microtiter plates. 2 (SARS-CoV-2), has triggered a worldwide pandemic with over 176 million confirmed cases globally and more than 3.8 million deaths as of June 2021 [1] In response to this major public health crisis, global efforts have been dedicated to developing different SARSCoV-2 vaccines using a variety of technologies [2,3,4,5,6] and the SARS-CoV-2 spike protein (S protein).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
